News

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader

Dec 3, 2025•Press Release

– LRK-4189, which targets PIP4K2C, a key cancer cell fitness target, is being developed for microsatellite stable (MSS)...

Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting

Aug 20, 2025•Press Release

– First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter   Cambridge, MA, August 20, 2025 – La...

Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024

Mar 28, 2024•Press Release

– LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in ...

Oncology’s Next Frontier: ADCs, Radiopharma and the Future of Cancer Treatment

Jan 10, 2024•PRESENTATION PLAYBACK

Fierce JPM Week panel (3:40pm PST) with CEO Catherine Sabatos-Peyton and other industry experts from Merck, Abbvie and more (...

Larkspur Biosciences Announces CEO Catherine Sabatos-Peyton to Participate in Upcoming Biotech Events

Dec 14, 2023•Press Release

Watertown, MA — December 14, 2023 – Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops im...